Nivolumab Immunotherapy Plus Hydrogen Inhalation For Treatment Of Kras-Mutant Pulmonary Sarcomatoid Carcinoma: A Case Report

Background: Pulmonary sarcomatoid carcinoma (PSC) as a rare subtype of nonsmall cell lung cancer (NSCLC) is resistant to conventional chemotherapy and radiotherapy with poor prognosis. Nivolumab is a monoclonal antibody against PD-1 and might be a valuable therapy option for PSC, but limited case reports have shown good response.Case presentation: A 61-year-old man with PSC characterized with KRAS-G12C mutation and TP53 mutation received treatment of nivolumab synchronously combined with hydrogen inhalation. Clinical symptoms gradually relieved, and evaluation on imaging revealed a response after 1 year.Conclusion: This case suggests that immunotherapy combined with hydrogen inhalation may potentially be a promising strategy to treat PSC patients.